Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers
NCT07598968Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanlim Pharm. Primary endpoint: Area Under the Concentration-Time Curve over the Dosing Interval at Steady State. Started Jun 2023; status: completed.
02
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07598968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598968.